USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment
Summary
The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.
What changed
This document is a USPTO patent application (US20260083761A1) filed on September 8, 2023, by Public University Corporation Nagoya City University. The application describes a pharmaceutical composition, a neuronal migration promoter, and a method for treating brain diseases by using a neuraminidase inhibitor to promote the migration of neurons. The abstract highlights the potential of this technology for neurological treatments.
As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical research and development, particularly in the area of neuroscience and brain disease treatment, should monitor the progress of this patent application and related technologies. The assignee and inventors are listed as Public University Corporation Nagoya City University, Kazunobu Sawamoto, and Mami Matsumoto.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION FOR TREATING BRAIN DISEASE, NEURONAL MIGRATION PROMOTER, AND USE THEREOF
Application US20260083761A1 Kind: A1 Mar 26, 2026
Assignee
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
Inventors
Kazunobu SAWAMOTO, Mami MATSUMOTO
Abstract
Provided is a technology capable of promoting migration of neurons. This pharmaceutical composition for treating a brain disease includes a neuraminidase inhibitor, this neuronal migration promoter includes a neuraminidase inhibitor, and this method of promoting migration of neurons includes a step of bringing a neuraminidase inhibitor into contact with neurons.
CPC Classifications
A61K 31/7012 A61K 9/0019 A61P 25/00
Filing Date
2023-09-08
Application No.
19110266
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.